In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effimune SAS

Division of OSE Immunotherapeutics SA
www.effimune.com

Latest From Effimune SAS

OSE Immunotherapeutics Seeks Partner For Lead Drug

Emerging Company Profile: Alexis Peyroles, chief operating officer of OSE Immunotherapeutics outlines the 2016-founded company's plans for commercializing its lead drug, Tedopi (OSE-2102).

StartUps and SMEs ImmunoOncology

OSE Immunotherapeutics And Servier Join Forces In Auto-Immune Field

French groups OSE Immunotherapeutics and Servier have inked a pact to develop and commercialize the newly formed biotech's interleukin-7 antagonist in ulcerative colitis.

Commercial Companies

OSE Immunotherapeutics To Bolster R&D, Post-Janssen Option

The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.

Deals Clinical Trials

Deal Watch: Exelixis Teams With Ipsen For Ex-US Commercialization Of RCC Candidate

Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • OSE Immunotherapeutics SA
  • Senior Management
  • Didier Coquoz, CEO & VP, Bus. Dev.
    Marc Moguilewsky, VP, Bus. Dev.
  • Contact Info
  • Effimune SAS
    Phone: 02 40 412834
    1 Rue Gaston Veil
    Nantes, 44035
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register